Emergence of Enzyme-based 2nd generation CGMS (1999) and limitations:

• Limitation on accuracy and persistence (calibration required twice-a-day)
• Economic burden due to short sensor replacement cycle (1 week)
• Time lag issues due to interstitial fluid-based measurements/li>
• Skin troubles due to sensor taping

2.5-generation CGMS implanted in the body

• June 2018, US FDA approved implantable CGMS Eversence from Senseonics
• FY2018 sales of Senseonics in the US: US$18.9M (about 20 billion won)

• Due to the limitations of the fluorescent material-based sensor, it needs to be replaced every 3 months.
• Still, the price per sensor is over $1,000, which is over $4,200 per year.
• Still, the problem of “time-lag”, a limitation of interstitial fluid (ISF)-based CGMS